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Abstract
Background: Despite some studies suggesting a possible association between human leukocyte antigen, HLA-
B*5801 and allopurinol induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), the
evidence of association and its magnitude remain inconclusive. This study aims to systematically review and meta-
analyze the association between HLA-B*5801 allele and allopurinol-induced SJS/TEN.
Methods: A comprehensive search was performed in databases including MEDLINE, Pre-MEDLINE, Cochrane
Library, EMBASE, International Pharmaceutical Abstracts (IPA), CINAHL, PsychInfo, the WHO International, Clinical
Trial Registry, and ClinicalTrial.gov from their inceptions to June 2011. Only studies investigating association
between HLA-B*5801 with allopurinol-induced SJS/TEN were included. All studies were extracted by two
independent authors. The primary analysis was the carrier frequency of HLA-B*5801 comparison between
allopurinol-induced SJS/TEN cases and each comparative group. The pooled odds ratios were calculated using a
random effect model.
Results: A total of 4 studies with 55 SJS/TEN cases and 678 matched-controls (allopurinol-tolerant control) was
identified, while 5 studies with 69 SJS/TEN cases and 3378 population-controls (general population) were found.
SJS/TEN cases were found to be significantly associated with HLA-B*5801 allele in both groups of studies with
matched-control (OR 96.60, 95%CI 24.49-381.00, p < 0.001) and population-control (OR 79.28, 95%CI 41.51-151.35,
p < 0.001). Subgroup analysis for Asian and Non-Asian population yielded similar findings.
Conclusion: We found a strong and significant association between HLA-B*5801 and allopurinol-induced SJS/TEN.
Therefore, HLA-B*5801 allele screening may be considered in patients who will be treated with allopurinol.
Keywords: Human leukocyte antigen, severe cutaneous reaction, Stevens-Johnson syndrome, toxic epidermal
necrolysis, allopurinol, meta-analysis
Background
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are severe manifestations of cutaneous
hypersensitivity reactions affecting approximately 0.4 to
6 persons per million populations each year [1-3].
Despite the low incidence, the mortality rate has been
estimated at 5% for SJS and 30-50% for TEN [2,4,5].
Clinical presentation of SJS and TEN is characterized by
a rapidly progressing, blistering exanthema accompanied
by mucosal involvement and systemic symptoms that
may present as fever, mild elevation of hepatic enzymes,
intestinal and pulmonary manifestations [6].
Medications are thought to be a major cause of SJS/
TEN cases (~80%). Chemical exposures, mycoplasma
pneumonia, viral infections, and immunizations have
also been implicated [2]. Iatrogenic causes that have
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dromes include: antiepileptic drugs, antibiotics, and uric
acid lowering agents [2,5]. A multinational case-control
study recently reported that allopurinol, a xanthine oxi-
dase inhibitor commonly used to treat hyperuricemia
and gouty arthritis, was the most frequent drug asso-
ciated with SJS and TEN [7].
The pathogenesis of allopurinol-induced SJS and TEN
is consistent with a delayed-type immune-mediated
reaction [2]. The pathogenesis, in conjunction with
observed familial predispositions to allopurinol-induced
SJS/TEN, alludes to potential genetic-based immunolo-
gical markers [8]. A number of gene-association investi-
gations have been conducted to elucidate the genetic
component of allopurinol-induced SJS/TEN. Results
from these studies suggest a strong association with the
human leukocyte antigen (HLA), HLA-B*5801 [9-15].
However, these previous studies have shown consider-
able variation among the magnitude of the association
between allopurinol-induced SJS/TEN and HLA-B*5801.
A major limitation of the individual studies stems from
the low incidence of allopurinol-induced SJS/TEN,
which generates observational studies with relatively
small sample sizes and insufficient power.
Given the recent accumulation of genetic association
studies, inconsistent results, and inadequate power, a
quantitative synthesis of the evidence is warranted. The
objective of this review is to systematically accumulate
and quantitatively analyze the genetic association
between HLA-B*5801 and allopurinol-induced SJS/TEN,
as well as to elucidate any between-study heterogeneity.
Methods
Data sources and search strategy
We performed systematic searches on the following
databases: MEDLINE, PreMEDLINE, Cochrane library,
International Pharmaceutical Abstracts (IPA), Excerpta
Medica Database (EMBASE), Cumulative Index to Nur-
sing and Allied Health Literature (CINAHL), World
Health Organization (WHO) International Clinical Trial
Registry, and ClinicalTrials.gov from its inception until
June 2011. The search terms used were “HLA-B” OR
“Human leukocyte antigen” with AND “allopurinol”
AND “Stevens Johnson Syndrome” OR “Toxic Epidermal
Necrolysis” OR their acronyms. The Medical Subject
Headings (MeSH) was employed when searching data-
base with such option available. Language of the pub-
lished papers was not restricted and only human studies
were included. Bibliographies of the included articles
were examined to identify additional studies.
Study selection
Two reviewers independently evaluated titles and
abstracts retrieved from the comprehensive searches for
inclusion. Disagreements were resolved by group con-
sensus. To be included, studies were required to meet-
ing the following criteria: 1) investigated the association
between HLA-B*5801 and allopurinol-induced SJS/TEN;
2) reported data sufficient for calculating carrier fre-
quency of HLA-B*5801 among cases and controls; 3)
cases were subjects that were defined according to
detached body surface area as SJS (< 10%), SJS/TEN
overlap (10-30%) and TEN (> 30%) [16-18]. Animal stu-
dies, case reports, review articles, and duplicate studies
were excluded.
Data extraction and quality assessment
All articles were extracted independently by reviewers
(RS, EEE), and discrepancies were resolved through dis-
cussion. The following data were extracted from each
study: study design, eligibility criteria, diagnostic criteria
of SJS or TEN, selection of cases and controls, patient
demographics, genotyping technique, and main results.
We used Newcastle-Ottawa quality assessment scale
[19] for assessing the quality of included observational
studies in this review.
Data analysis
The overall odds ratios (ORs) with corresponding 95%
confidence intervals (CIs) were calculated to determine
the association between the presence of HLA-B*5801 in
at least one allele and allopurinol-induced SJS/TEN. In
some studies [11,12], allele frequency data were pre-
sented. Based on a study of Tanaka et al [20] and data-
base of Major Histocompatibility Complex [8], we
converted allele frequency data into the number of
patients with HLA-B*5801 present in at least one allele.
All analyses were performed using DerSimonian and
Laird method [21] under a random-effects model. Sensi-
tivity analyses were also performed to determine the
robustness of the findings by ethnicity. The analyses
were also performed separately for those using different
types of control groups (e.g. controls obtained from the
study, controls obtained from the population database).
Statistical heterogeneity was assessed via the Q-statistic
and I-squared tests [22]. A Q-value of 0.10 indicated
statistically significant between-study heterogeneity and
I-squared values < 25% denoted no/minimal heterogene-
ity across studies. Begg’s test and Egger’s test were used
to evaluate the publication bias [23,24].
Results
Study selection
A total of 94 articles were identified. After exclusion of
duplication (6 articles), review articles or case reports
(59 articles), non-human studies (1 article), studies in
which patients did not receive allopurinol (5 articles),
studies which did not examine the association between
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Page 2 of 10HLA-B*5801 genotype and SJS or TEN outcomes (14
articles) and studies which did not have comparator (3
articles), 6 remaining studies included in the meta-ana-
lysis [10-15] (Figure 1). No additional articles were iden-
tified via review of the bibliographies of included
studies.
Study Characteristics
Characteristics of included studies are summarized in
Table 1 and Table 2. All studies [10-15] included 96
SJS/TEN cases, 678 matched-controls and 3378 popula-
tion-controls. The reported average age was 57.4 years
old (range from 50.0-70.9 years) [10-15] and 51.6 years
old (range from 35.9-63.5 years) [10,13-15] for cases and
matched-control, respectively. Most patients were men
(58.3% for cases and 77.7% for matched-controls).
Kaniwa et al [11] and Lonjou et al [12] did not report
gender percentage and mean age in the control groups.
All SJS/TEN cases in all 6 studies were diagnosed
according to the consensus definition [16-18]. All cases
required confirmation of diagnosis by dermatologist
[10,13], allergy specialist [15], Japan Severe Adverse
Reaction (JSCAR) research group [11], or RegiSCAR
expert committee [12]. All studies, except Kaniwa et al
[11], required specific criteria for allopurinol exposure
for the case definition. They included the duration of
exposure to allopurinol no longer than 42 days [12], 60
days [15], or 3 months [10,13], and improvement of
symptoms after drug discontinuation [10,13]. Hung et al
[7] was the only study specifying that patients without
symptoms upon re-exposure must be excluded. Despite
a requirement of being exposed to allopurinol of cases,
three studies [11-13] reported no information on dose
of allopurinol and four studies [10,13-15] did not
reported the actual duration of allopurinol exposure in
both cases and controls.
Three studies [10,13,14] employed classical case con-
trol approach in which controls were matched on hospi-
tal. In addition, all controls must have used allopurinol
at least 6 months without the evidence of any cutaneous
reactions. Five studies [10,12-15] also conducted a case
control study but used general population as a control
group (Table 1). Five studies [10,11,13-15] examined
subjects of Asian descent, whereas Lonjou et al [12]
examined mixed European population. Hung et al [10]
studied Han Chinese population in Taiwan, while
Kaniwa et al [11] and Tassaneeyakul et al [13] investi-
gated in Japanese and Thai populations, respectively. In
a d d i t i o n ,K a n ge ta l[ 1 4 ]a n dJ u n ge ta l[ 1 5 ]s t u d i e di n
Korean population.
All studies determined HLA-B*5801 in cases using
PCR-based genotyping and sequence-based typing meth-
ods. Since two studies [11,12] used population-controls,
there were no descriptions on how genetics of controls
were assessed. All studies [11-15] used blood as samples
for genotyping, except Hung et al [10] which did not
report the source of genetic material. None of the
included studies described a blinding procedure for per-
sonnel performing genotyping.
Quality assessment
The methodological quality of all studies was shown as
mean Newcastle-Ottawa scale of 5 (range from 3 to 7;
maximum possible score, 9) (Table 1). Four studies
[10,13-15] using matched controls had scores range
from 4-7, while the other two studies [11,12] utilizing
population controls received lower quality score of 3.
Quantitative synthesis
Four studies with 55 SJS/TEN cases and 678 matched-
controls were included in the comparisons of carrier fre-
quency to examine the gene association between cases
and allopurinol-tolerant controls [10,13-15]. For these 4
studies, the number of HLA-B*5801 carriers was 54/55
and 74/678 among cases and controls, respectively. Five
studies [10-12,14,15] with 69 SJS/TEN cases and 3378
population-controls were included in a separate analysis
of carrier frequency to test the association of the HLA-
B*5801 genotype and allopurinol induced-SJS/TEN com-
pared to the general population. Cumulative carrier fre-
quency for these three studies was 50/69 for cases and
171/3378 for population-controls, respectively.
Table 3 summarizes the results of all comparisons. All
studies demonstrated a statistically significant associa-
tion between HLA-B*5801 and allopurinol-induced SJS/
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database searching 
(n =94) 
Records after duplicates removed  
(n = 88)
Full-text articles assessed 
for eligibility  
(n = 88) 
Full-text articles excluded, with 
reasons (n = 82) 
Review article or case report 
(n=59) 
Not human study (n=1) 
Not receiving allopurinol (n=5) 
Not reporting association 
between HLA-B*5801 and SJS 
or TEN (n=14) 
No comparator (n=3) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 6) 
Figure 1 A flow diagram for study identification, inclusion and
exclusion.
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Page 3 of 10Table 1 Characteristics of studies included in the meta-analysis
Author Year Study Design SJS/TEN Cases
a(n) Controls Data Collection Specific Requirement for Case
Allopurinol-Exposure
b
Matching Criteria NOS
Matched(n) Population(n) SJS/TEN Cases Controls
Hung SI [10] 2005 Case-control 21 135 93
c R R Yes Drug, hospital 7
Kaniwa N [11] 2008 Case-population control
d 10 - 493
e R- N R - 3
Lonjou C [12] 2008 Case-population control
d 31 - 1822
f R (N = 70), P (N = 80) - Yes - 3
Tassaneeyakul W [13] 2009 Case-control
g 27 54 - R R Yes Drug, hospital 7
Kang HR [14] 2011 Case-control 5 57 485
h R R Yes Drug, hospital 4
Jung JW [15] 2011 Retrospective cohort 2 432 485
h R R Yes Drug, hospital 6
Abbreviation: R = retrospective, P = prospective, NOS = Newcastle-Ottawa Scale, NR = not report
a Only patients that received drugs of interest (Allopurinol) were included.
b Including: maximum time to develop adverse drug reaction (ADR) from drug initiation [10,12,13], improvement of symptom upon drug discontinuation [10,13], and exclusion of patients without symptoms upon re-
exposure [10].
c Healthy subjects randomly selected from a biobank under nationwide population study, in which 3312 Han Chinese descendants were recruited based on the geographic distribution across Taiwan. There was no self-
report of adverse drug events by any of the population control.
d Using population based as control group.
e Data of healthy Japanese reported by Tanaka H, et al. [20].
f Using allele frequencies from European populations available on dbMHC: http://www.ncbi.nlm.nih.gov/projects/mhc/ihwg.cgi
g Author described the study as cross-sectional case-control study.
h Using allele frequency from the general population of Korea.
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0Table 2 Patients’ demographic information
Author Year % Male Mean age,
yr (range)
Ethnicity Country Allopurinol Dose, mg/day
(range)
Actual Duration of Allopurinol
Exposure
SJS/TEN Cases Controls SJS/TEN Cases Controls Cases Control Cases Control
Hung SI [10] 2005 52.4 92.6
a 62.4 (25-91) 56.0 (21-84)
b Han Chinese Taiwan 100
(50-300)
150
(100-400)
26 d
(~1-56 d)
22 m
(6-107 m)
Kaniwa N [11] 2008 80.0 NA 70.9 (53-83) NA Japanese Japan NR NR NR NR
Lonjou C [12] 2008 58.1 NA 55.0 (21-83) NA Mixed European Population
c NR NR NR NR NR
Tassaneeyakul W [13] 2009 55.6 79.63 65.0 (38-81) 63.5 (46-90) Thai Thailand NR NR 14 d
(3-50 d)
26 m
(3-600 m)
Kang HR [14] 2011 60.0 64.9
d 50.0 (42-80) 51.0 (20-76)
d Korean Korea 200
(100-300)
100
(50-200)
0.7 m
(0.2-1.1 m)
29.1 m
(6-72 m)
Jung JW [15] 2011 43.8 73.6
d 41.4 (27-56) 35.9 (18-54)
d Korean Korea 112.5
(74-151)
100
(50-150)
59 d
(14-105 d)
887 d
(66-1708 d)
Abbreviations: SJS = Stevens-Johnson Syndrome, TEN = Toxic Epidermal Necrolysis; NR = No Report; NA = Not Applicable; d = day(s); m = month(s)
a The percent male of matched-controls (% male in population controls is 55.91).
b Mean age in matched-controls (mean age in population controls is 53.9 (22-91)).
c Including Asian, South American, African, and European.
d The values from matched-controls group.
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0TEN. In the primary analyses, SJS/TEN cases were sig-
nificantly more likely to carry HLA-B*5801 allele com-
pared with both matched-control (OR 96.60, 95%CI
24.49-381.00, p < 0.001) and population-control (OR
79.28, 95%CI 41.51-151.35, p < 0.001) (Figure 2). There
was no apparent publication bias as revealed by Begg’s
and Egger’s test (Egger’s test for bias, p = 0.732 and
Begg’s test for bias p = 0.602). No statistically significant
heterogeneity was found based on I-squared (I
2 =0 . 0 % )
and Q-statistics (p = 0.482 for matched-control and p =
0.751 for population-control).
Sensitivity analyses
Subgroup analysis for Asian and non-Asian population
cohorts revealed similar findings. Analyses demonstrated
a statistically significant association between allopurinol-
induced SJS/TEN with the summary odds ratio of 74.18
(95%CI 26.95-204.14) and 101.45 (95% CI 44.98-228.82)
for Asian and non-Asian populations, respectively.
Discussion
Our findings indicate that HLA-B*5801 allele is signifi-
cantly associated with increased risk of developing SJS/
TEN in patients using allopurinol. This severe adverse
event associated with allopurinol could be prevented if
such genetic information is known a priori. Clinicians
and policy makers may use our findings as a foundation
to support the implementation of genetic testing prior
to initiation of allopurinol.
These findings reveal that the risk of developing SJS/
TEN among those allopurinol users with HLA-B*5801 is
significantly increased by 80-97 times compared to those
without the gene. The sensitivity analyses suggested that
the summary odds ratios remained significant regardless
of populations. These findings are suggestive of the
potential of genotyping in a wide range of population.
Several strengths of our research work deserve more
discussion. First, our study is the first one including all
kinds of studies determining association of HLA-B*5801
and SJS/TEN development. Second, all SJS/TEN cases
were in accordance with the consensus definition
[16-18]. These stringent inclusion criteria lowered the
risk of misclassification, resulting in increased reliability
of our research findings. Third, our meta-analysis
adopted the Newcastle-Ottawa scale [19] as a tool to
evaluate quality of all case control studies. The Newcas-
tle-Ottawa approach has been reported in several arti-
cles to have a good validity for assessing the
observational study [25-28]. The average quality score of
5 represented a good quality of overall evidence.
Table 3 Number of patients who had HLA-B*5801 allele positive and summary odds ratios
Author Year HLA-B*5801
Positive/Total
Odds Ratio (OR) 95% Confidence Interval
SJS/TEN Cases
(n)
Controls
(n)
Matched-control
Hung SI [10] 2005 21/21 20/135 242.27 14.11-4158.76
Tassaneeyakul W [13] 2009 27/27 7/54 348.33 19.15-6336.86
Kang HR [14] 2011 4/5 6/57 34.00 3.25-356.12
Jung JW [15] 2011 2/2 41/432 47.17 2.23-999.15
Pooled OR 96.60 24.49-381.00
Population-control
Hung SI [10] 2005 21/21 19/93 164.28 9.52-2833.92
Kaniwa N [11] 2008 4/10 6/493 54.11 12.08-242.41
Lonjou C [12] 2008 19/31 28/1822 101.45 44.98-228.82
Kang HR [14] 2011 4/5 59/485 28.88 3.17-262.79
Jung JW [15] 2011 2/2 59/485 35.84 1.70-755.61
Pooled OR 79.28 41.53-151.35
Abbreviations: SJS = Stevens-Johnson Syndrome, TEN = Toxic Epidermal Necrolysis; OR = Odds Ratio
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Figure 2 Forest plot. A forest plot demonstrating the association
between HLA-B*5801 and allopurinol-induced SJS/TEN in matched-
and population-control of included studies.
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Page 6 of 10Meta-analysis is not only pooling studies’ findings, but
this analysis can also determine heterogeneity occurred
among the selected studies. The results from our sensi-
tivity analysis demonstrated no significant heterogeneity
among populations despite differences in their allele fre-
quency between Asian and non-Asian. Thus, it is justi-
fied to perform such analysis despite similarity in the
trend of results from the chosen reports. Our findings
revealed that despite some differences in several charac-
teristics (e.g. race, sources and selection of control), the
association is still consistent and suitable for pooling
using meta-analytic technique [29].
Despite the absence of statistical significance of publi-
cation bias tests, a possible existence of publication bias
cannot be excluded. Because of a relatively small num-
ber of total sample size and limited number of studies,
the power of publication bias tests might not be suffi-
cient. Even though the meta-analysis shows a consistent
significant association of HLA-B*5801 and SJS/TEN in
all studies, the overall estimates should be interpreted
with caution.
One interesting debate ongoing regarding association
between HLA-B*5801 on the risk of developing SJS/TEN
is its nature. It has been proposed by Hung et al [10]
that HLA-B*5801 was necessary but might not be the
only factor related to the risk of SJS/TEN development.
Lonjou et al [12] stated that the gene was an important
element, but it was neither necessary nor sufficient. All
cases in three studies [10,13,15] had HLA-B*5801 allele,
whereas the prevalence ranged from 40-80% among
cases in the other 3 studies [11,12,14]. The lack of HLA-
B*5801 in some cases in the latter 3 studies made it
clear that such gene was not the sole factor required.
We believe that SJS/TEN development is multifactorial.
Other factors including other genes and environment
might have a role in the development. What we can
conclude was consistent with the summary of Hung et
al [10], which was that HLA-B*5801 had a significant
role in SJS/TEN occurrence. More research is necessary
to further elucidate on how this gene and other factors
are involved in allopurinol-induced SJS/TEN
pathogenesis.
The increased risk of developing SJS/TEN in those
subjects with HLA-B*5801 can be explained by the
involvement of cytotoxic T-cells and amplification fol-
lowing cytolytic cytokine. The pathogenesis of drug
hypersensitivity is postulated to have direct involvement
with human leukocyte antigen (HLA) genes [9,30]. HLA
genes located on the major histocompatibility complex
(MHC) region of the human chromosome 6p21.3, play a
central role in the immune reaction by presenting an
antigen to the T cell receptor (TCR) [30].
Despite several postulated mechanisms for the associa-
tion of HLA-B*5801 and allopurinol-induced SJS/TEN,
thus far, there is no definitive proven mechanism. None-
theless, an immunologic mechanism might play a role in
SJS/TEN development [31-33]. Several protein mole-
cules play an important role in this complex process.
For instance, MHC proteins, T-cell receptors and some
cellular drug metabolizing enzymes (i.e. cytochrome
P450 and Phase II metabolizing enzymes) can contribute
to the hapten formation and ensuing immunological
responses [34]. Although, when the hapten is completely
d e v e l o p e da n dp r e s e n t e da tt h es u r f a c eo fan a s c e n tT -
cell and B-cell clone, they need to proliferate and fully
exert their cellular actions. Thus, the fate of these cells
can determine the final outcome [35]. These cells may
divide and expand resulting in the final immune
responses, or get into apoptosis and die out. To eluci-
date this clonal selection/expansion event among T-cells
and B-cells in the SJS/TEN development, a stochastic
behavior of the cells is possible [36]. Therefore, a
mathematic model describing clonal selection/expansion
processes may be useful [37-39]. Nevertheless, this cellu-
lar event of the clonal selection/expansion may contri-
bute to the low incidence of SJS/TEN observed in the
general population.
Apart from the fate of the nascent antigen specific T-
and B-cells, downstream events after binding between
the HLA-B*5801 and its receptor may influence the T-
cell stimulation. As HLA-B*5801 is presented at the sur-
face, it requires T-cell receptor to couple with the anti-
gen. Subsequently, the immunological system is
stimulated [10,30]. The lack of SJS/TEN development
might be explained by a malfunction of the T-cell recep-
tor, which could be due to T-cell receptor polymorph-
ism [40,41]. Another putative cause might be an
existence of a gene exerting inhibitory effect, resulting
in lower risk of SJS/TEN development. In a study of
Alfirevic and colleagues [42] investigating the associa-
tion between genes and SJS/TEN among carbamezepine
(CBZ) users, despite small sample size, among those
whose possess HLA-B*0702, a significant protective
effect for the development of severe reaction was
reported. The mechanism of this protective effect is not
fully understood.
The association between HLA-B*5801 allele and allo-
purinol-induced SJS/TEN is consistent across different
populations, both Asian and non-Asian [10-15],
whereas, an association between HLA-B*1502 and CBZ-
induced SJS/TEN demonstrated less consistency
[12,43,44]. HLA-B*1502 allele, whose an association with
CBZ-induced SJS/TEN is significant in most Asian
populations, but not in Japanese and European popula-
tion. These discrepancies might be explained by the dif-
ferent genetic background. Since this gene is also
present in many populations (i.e. African, Caucasian,
and Asian), therefore, the association of HLA-B*5801
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v a r i o u se t h n i cg r o u p s .O nt h eo t h e rh a n d ,HLA-B*1502
allele is only present in limited populations (i.e. Asian
population) [45].
Interestingly, HLA-B*5801 has a more pronounced
effect on allopurinol-induced SJS/TEN compared to
those found in the case of HLA-B*1502 and CBZ-
induced SJS/TEN. In the latter case, the incidence may
be associated with other contributing factors (i.e. other
genes) to trigger the adverse drug reaction, whereas
those factors may play less role in initiating SJS/TEN in
case of HLA-B*580. A study in Japan [46] reported that
CBZ-induced SJS/TEN was associated with HLA-
B*1511, a member of HLA-B75 type that also includes
HLA-B*1502, HLA-B*1508, HLA-B*1515, HLA-B*1521,
HLA-B*1530, and HLA-B*1531. These suggested that
not only HLA-B*1502 but also other HLA-B75 members
are risk factors for CBZ-induced SJS/TEN. By compari-
son, the strong association between HLA-B*5801 and
allopurinol-induced SJS/TEN has been validated in dif-
ferent populations and may be a universal phenomenon
since it has been identified in all Chinese, Japanese,
Thai, Korean and European patients [10-15].
Notably, a main caveat in this study is the potential
misinterpretation of our research findings. This meta-
analysis revealed the significant association of HLA-
B*5801 allele and the increased risk of allopurinol-
induced SJS/TEN. This does not mean that having
HLA-B*5801 test done will result in absolutely no risk
of allopurinol-induced SJS/TEN. Monitoring of signs
and symptoms in these patients are still needed.
Our study is also only limited to the investigation of
the association between HLA-B*5801 and allopurinol-
induced SJS/TEN. In fact, there has been a number of
studies reporting a potential association of DRESS (Drug
Rash with Eosinophillia and Systemic Symptoms) and
HLA-B*5801 [10,47]. The interpretation of our findings
should be limited to SJS/TEN cases and not be general-
izable to other severe cutaneous adverse reactions
(SCARs).
The implications of our research findings are more
likely significant among population with high prevalence
of HLA-B*5801. Based on the strong association of the
presence of HLA-B*5801 alleles and SJS/TEN, it is pre-
sumed that the attributable risk of SJS/TEN due to the
existence of this gene is larger among those with the
gene. Allele frequency was reported as high as 6-8%
among Southeast Asian population and < 1% among
Western European population [8,45]. From our results,
a genotypic testing of the HLA-B allele may have a ben-
efit to the patients before receiving the drug; particularly
in high risk population (e.g. Asian). Knowing the HLA-B
allele status of allopurinol users may guide clinicians in
determining the optimal choice in order to lower the
likelihood of allopurinol-induced SJS/TEN. Presumably
these events are avoidable; it might be prudent to con-
sider whether such genetic test should be adopted into
routine practice in high-risk population. In order to
convince the policy makers to support such genetic test-
ing, a formal cost-effectiveness analysis is warranted.
Conclusions
We found a strong association between HLA-B*5801
allele and allopurinol-induced SJS/TEN in both Asian
and non-Asian population. Knowing the HLA-B allele
status may be beneficial to some groups of patients who
are about to start receiving allopurinol as such informa-
tion may help clinicians in determining the optimal
drug therapy.
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